The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | Challenges in the treatment of multiple myeloma in Brazil
In this video, Angelo Maiolino, MD, PhD, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, comments on the evolving treatment landscape for multiple myeloma (MM) in Brazil, highlighting the challenge of unequal access to novel treatments between the public and private healthcare sectors. Prof. Maiolino also notes the potential benefits of CAR T-cell therapy, despite its high cost, and the development of an academic initiative to make CAR-T more accessible to patients in Brazil. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, in the Brazilian perspective, the bispecifics and CAR-T are both approved and also daratumumab, pomalidomide and so on. But in Brazil, you know, access to the modern treatments are still a challenge, in particular in the public health system. For the public, the transplant is still a major backbone for the patients. So for the public health system, unfortunately, we don’t have access to, for example, to lenalidomide and daratumumab yet...
So, in the Brazilian perspective, the bispecifics and CAR-T are both approved and also daratumumab, pomalidomide and so on. But in Brazil, you know, access to the modern treatments are still a challenge, in particular in the public health system. For the public, the transplant is still a major backbone for the patients. So for the public health system, unfortunately, we don’t have access to, for example, to lenalidomide and daratumumab yet. So this is a system, an unfair system. For the private, we have.
So I think in the near future, certainly we need to have approval at least for lenalidomide and daratumumab for the public. I hope that it can happen in the next few years. But CAR-T will still be a challenge, also for the private because of the high cost of the treatment. But, you know, the CAR-T is a one-shot treatment. It’s not a continuous treatment. And maybe the cost-effectiveness of the CAR-T could be an opportunity also. And it’s very effective, particularly in the first lines of treatment. Maybe not in the first, but at least at the first relapse. So it will be an important tool. In Brazil also you have developed an academic initiative of CAR-T. So we will have in the future the commercial and the academic CAR-T and we hope that we can have CAR-T access for patients from the public and also from the private sector.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
